Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TBE Vaccine Booster in Adults
NCT00387634Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Primary completion
- Oct 2011
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of tick-borne encephalitis vaccine in tick-borne encephalitis (TBE) (4 arms), sponsored by Novartis. Primary endpoint: immunogenicity of TBE vaccine for adults when given as first booster dose as measured by neutralisation test and ELISA at Year 5. Started Sep 2006; status: completed.
02
Drugs
tick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00387634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387634.